KalVista Pharmaceuticals (NASDAQ:KALV) CEO Benjamin Palleiko Sells 10,926 Shares of Stock

KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) CEO Benjamin Palleiko sold 10,926 shares of KalVista Pharmaceuticals stock in a transaction dated Friday, May 22nd. The shares were sold at an average price of $26.78, for a total value of $292,598.28. Following the completion of the transaction, the chief executive officer owned 479,989 shares in the company, valued at $12,854,105.42. This trade represents a 2.23% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

KalVista Pharmaceuticals Price Performance

KALV opened at $26.81 on Wednesday. The business’s 50-day moving average is $21.74 and its two-hundred day moving average is $17.54. KalVista Pharmaceuticals, Inc. has a 1 year low of $9.83 and a 1 year high of $26.85. The company has a debt-to-equity ratio of 8.18, a current ratio of 5.17 and a quick ratio of 5.10. The firm has a market capitalization of $1.43 billion, a PE ratio of -7.75 and a beta of -0.12.

KalVista Pharmaceuticals (NASDAQ:KALV) last released its quarterly earnings results on Thursday, May 14th. The specialty pharmaceutical company reported ($0.43) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.38) by ($0.05). The firm had revenue of $39.17 million for the quarter, compared to analyst estimates of $39.03 million. Research analysts anticipate that KalVista Pharmaceuticals, Inc. will post -0.96 earnings per share for the current fiscal year.

Institutional Investors Weigh In On KalVista Pharmaceuticals

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in KALV. Parallel Advisors LLC raised its stake in KalVista Pharmaceuticals by 45.8% in the first quarter. Parallel Advisors LLC now owns 1,876 shares of the specialty pharmaceutical company’s stock valued at $38,000 after buying an additional 589 shares during the last quarter. BNP Paribas Financial Markets raised its stake in KalVista Pharmaceuticals by 47.0% in the second quarter. BNP Paribas Financial Markets now owns 4,041 shares of the specialty pharmaceutical company’s stock valued at $46,000 after buying an additional 1,292 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank purchased a new stake in KalVista Pharmaceuticals in the third quarter valued at about $55,000. Royal Bank of Canada raised its stake in KalVista Pharmaceuticals by 137.0% in the first quarter. Royal Bank of Canada now owns 2,917 shares of the specialty pharmaceutical company’s stock valued at $59,000 after buying an additional 1,686 shares during the last quarter. Finally, Truvestments Capital LLC raised its stake in KalVista Pharmaceuticals by 253.8% in the fourth quarter. Truvestments Capital LLC now owns 4,684 shares of the specialty pharmaceutical company’s stock valued at $76,000 after buying an additional 3,360 shares during the last quarter.

Analyst Upgrades and Downgrades

A number of research firms recently commented on KALV. Stifel Nicolaus increased their target price on shares of KalVista Pharmaceuticals from $39.00 to $42.00 and gave the company a “buy” rating in a research report on Thursday, March 26th. Needham & Company LLC cut shares of KalVista Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Thursday, April 30th. Weiss Ratings reissued a “sell (d-)” rating on shares of KalVista Pharmaceuticals in a research report on Tuesday, April 21st. Citizens Jmp cut shares of KalVista Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, April 29th. Finally, JonesTrading cut shares of KalVista Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Thursday, April 30th. Three research analysts have rated the stock with a Buy rating, five have issued a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, KalVista Pharmaceuticals presently has an average rating of “Hold” and a consensus target price of $30.60.

About KalVista Pharmaceuticals

KalVista Pharmaceuticals is a clinical‐stage biotechnology company focused on the discovery and development of small‐molecule protease inhibitors for orphan and specialty disease indications. The firm’s scientific platform centers on selective inhibition of plasma kallikrein, a serine protease implicated in disorders characterized by vascular leak, edema and inflammation. KalVista’s approach leverages oral and intravitreal delivery formats to target both systemic and ophthalmic conditions.

The company’s lead programs include an oral plasma kallikrein inhibitor in clinical trials for the acute treatment of hereditary angioedema (HAE) attacks and an intravitreal kallikrein inhibitor being evaluated for diabetic macular edema.